Key clinical point: Treatment of atrial fibrillation patients with a combination of non–vitamin K antagonist oral anticoagulant plus single antiplatelet therapy yielded no increase in risk of major adverse cardiac events.
Major finding: No differences in adverse cardiac events occurred in a comparison of triple antithrombotic therapy with dual antiplatelet therapy (DAPT) plus a vitamin K antagonist (VKA) vs. non–vitamin K antagonist oral anticoagulant (NOAC) plus single antiplatelet therapy (SAPT), with a hazard ratio 1.07, but clinically significant bleeding was lower in the NOAC plus SAPT patients (hazard ratio 0.56).
Study details: The data come from a meta-analysis of four randomized, controlled trials including 10,969 atrial fibrillation patients who underwent percutaneous coronary intervention.
Disclosures: The study received no outside funding. Lead author Dr. Capodanno disclosed relationships with Bayer, Daiichi Sankyo, AstraZeneca, and Sanofi Aventis.
Capodanno D et al. J Am Heart Assoc. 2020 Aug 18. doi: 10.1161/JAHA.120.017212.